<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445639</url>
  </required_header>
  <id_info>
    <org_study_id>BTH-NICU-2011-02</org_study_id>
    <secondary_id>2009-03-28</secondary_id>
    <nct_id>NCT01445639</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in Patients After Intracranial Surgery</brief_title>
  <official_title>Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine is a highly selective a2-adrenoreceptor agonist that produces dose-dependent
      sedation and analgesia without respiratory depression. Dexmedetomidine has been used in
      critically ill medical, surgical, and pediatric patients. No study has been designed
      specifically to evaluate dexmedetomidine uses in the neurocritical care population. The
      primary objective is to evaluate the safety and efficacy of dexmedetomidine for prophylactic
      analgesia and sedation in patients after intracranial surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PASTrial is a non-commercial, multi-center, randomized, placebo-controlled, double
      blinded clinical trial. The study compares dexmedetomidine versus normal saline (placebo) in
      patients after intracranial surgery with delayed extubation. In dexmedetomidine group,
      infusion (0.4μg/kg/h) is started when patients are admitted to neuro-intensive care unit for
      postoperative recovery. In control group, patients receive normal saline infusion at the same
      rate and volume in dexmedetomidine group. The patient's level of sedation is assessed by
      Sedation-Agitation Scale (SAS) per hour. Midazolam is administered in 0.3-0.5 mg bolus or
      continuous infusion as SAS above 4. The study is designed primarily to compare the percentage
      of patients with agitation and requiring midazolam infusion in the 2 study arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage of hours of optimal sedation.</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Optimal sedation is defined as SAS score 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with agitation and receiving additional sedatives.</measure>
    <time_frame>During the first 24 hours postoperatively</time_frame>
    <description>Agitation is defined as SAS above 4. Patients are given midazolam as agitation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of patients with adverse events.</measure>
    <time_frame>During the first 24 hours postoperatively</time_frame>
    <description>Adverse events include hypotension, bradycardia, airway obstruction, apnea, and consciousness disorders</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>as placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients after intracranial surgery with delayed extubation

        Exclusion Criteria:

          -  emergency operation

          -  brain stem operation

          -  preoperative consciousness disorders or epilepsy

          -  bradycardia, hypotension, acute myocardial infarction, second- or third degree heart
             block, or need continuous infusions of vasopressor before the start of study drug
             infusion

          -  patients enrolled in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-Xin Zhou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Neuro-ICU, Beijing Tiantan Hospital, Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuro-ICU, Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>January 25, 2014</last_update_submitted>
  <last_update_submitted_qc>January 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Xin Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>sedation</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>postoperative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

